|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yang X, Chen BB, Zhang MH and Wang XR:
MicroRNA-126 inhibits the proliferation of lung cancer cell line
A549. Asian Pac J Trop Med. 8:239–242. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ni T, Mao G, Xue Q, Liu Y, Chen B, Cui X,
Lv L, Jia L, Wang Y and Ji L: Upregulated expression of ILF2 in
non-small cell lung cancer is associated with tumor cell
proliferation and poor prognosis. J Mol Histol. 46:325–335. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Peters S, Adjei AA, Gridelli C, Reck M,
Kerr K and Felip E; ESMO Guidelines Working Group: Metastatic
non-small-cell lung cancer (NSCLC): ESMO Clinical Practice
Guidelines for diagnosis, treatment and follow-up. Ann Oncol.
23(Suppl 7): vii56–vii64. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang T, Zhang DM, Zhao D, Hou XM, Liu XJ,
Ling XL and Ma SC: The prognostic value of osteopontin expression
in non-small cell lung cancer: A meta-analysis. J Mol Histol.
45:533–540. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Leidinger P, Galata V, Backes C, Stähler
C, Rheinheimer S, Huwer H, Meese E and Keller A: Longitudinal study
on circulating miRNAs in patients after lung cancer resection.
Oncotarget. 6:16674–16685. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cai J, Fang L, Huang Y, Li R, Yuan J, Yang
Y, Zhu X, Chen B, Wu J and Li M: miR-205 targets PTEN and PHLPP2 to
augment AKT signaling and drive malignant phenotypes in non-small
cell lung cancer. Cancer Res. 73:5402–5415. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pisters KM, Evans WK, Azzoli CG, Kris MG,
Smith CA, Desch CE, Somerfield MR, Brouwers MC, Darling G, Ellis
PM, et al: Cancer care Ontario and American society of clinical
oncology adjuvant chemotherapy and adjuvant radiation therapy for
stages I–IIIA resectable non small-cell lung cancer guideline. J
Clin Oncol. 25:5506–5518. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fiori ME, Barbini C, Haas TL, Marroncelli
N, Patrizii M, Biffoni M and De Maria R: Antitumor effect of
miR-197 targeting in p53 wild-type lung cancer. Cell Death Differ.
21:774–782. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hatley ME, Patrick DM, Garcia MR,
Richardson JA, Bassel-Duby R, van Rooij E and Olson EN: Modulation
of K-Ras-dependent lung tumorigenesis by MicroRNA-21. Cancer Cell.
18:282–293. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Seike M, Goto A, Okano T, Bowman ED,
Schetter AJ, Horikawa I, Mathe EA, Jen J, Yang P, Sugimura H, et
al: MiR-21 is an EGFR-regulated anti-apoptotic factor in lung
cancer in never-smokers. Proc Natl Acad Sci USA. 106:12085–12090.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen C, Zhao Z, Liu Y and Mu D:
microRNA-99a is down-regulated and promotes proliferation,
migration and invasion in non-small cell lung cancer A549 and H1299
cells. Oncol Lett. 9:1128–1134. 2015.PubMed/NCBI
|
|
14
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Broderick JA and Zamore PD: MicroRNA
therapeutics. Gene Ther. 18:1104–1110. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Guo H, Ingolia NT, Weissman JS and Bartel
DP: Mammalian microRNAs predominantly act to decrease target mRNA
levels. Nature. 466:835–840. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mitchell PS, Parkin RK, Kroh EM, Fritz BR,
Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant
KC, Allen A, et al: Circulating microRNAs as stable blood-based
markers for cancer detection. Proc Natl Acad Sci USA.
105:10513–10518. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K,
Guo J, Zhang Y, Chen J, Guo X, et al: Characterization of microRNAs
in serum: A novel class of biomarkers for diagnosis of cancer and
other diseases. Cell Res. 18:997–1006. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kent OA and Mendell JT: A small piece in
the cancer puzzle: microRNAs as tumor suppressors and oncogenes.
Oncogene. 25:6188–6196. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
22
|
Ling DJ, Chen ZS, Zhang YD, Liao QD, Feng
JX, Zhang XY and Shi TS: MicroRNA-145 inhibits lung cancer cell
metastasis. Mol Med Rep. 11:3108–3114. 2015.
|
|
23
|
Yan LX, Huang XF, Shao Q, Huang MY, Deng
L, Wu QL, Zeng YX and Shao JY: MicroRNA miR-21 overexpression in
human breast cancer is associated with advanced clinical stage,
lymph node metastasis and patient poor prognosis. RNA.
14:2348–2360. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wan LY, Deng J, Xiang XJ, Zhang L, Yu F,
Chen J, Sun Z, Feng M and Xiong JP: miR-320 enhances the
sensitivity of human colon cancer cells to chemoradiotherapy in
vitro by targeting FOXM1. Biochem Biophys Res Commun. 457:125–132.
2015. View Article : Google Scholar
|
|
25
|
Schaar DG, Medina DJ, Moore DF, Strair RK
and Ting Y: miR-320 targets transferrin receptor 1 (CD71) and
inhibits cell proliferation. Exp Hematol. 37:245–255. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wu YY, Chen YL, Jao YC, Hsieh IS, Chang KC
and Hong TM: miR-320 regulates tumor angiogenesis driven by
vascular endothelial cells in oral cancer by silencing neuropilin
1. Angiogenesis. 17:247–260. 2014. View Article : Google Scholar
|
|
27
|
Cheng C, Chen ZQ and Shi XT: MicroRNA-320
inhibits osteosarcoma cells proliferation by directly targeting
fatty acid synthase. Tumour Biol. 35:4177–4183. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sun JY, Xiao WZ, Wang F, Wang YQ, Zhu YH,
Wu YF, Miao ZL and Lin YC: MicroRNA-320 inhibits cell proliferation
in glioma by targeting E2F1. Mol Med Rep. 12:2355–2359.
2015.PubMed/NCBI
|
|
29
|
Lupu R and Menendez JA: Targeting fatty
acid synthase in breast and endometrial cancer: An alternative to
selective estrogen receptor modulators? Endocrinology.
147:4056–4066. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Weiss L, Hoffmann GE, Schreiber R, Andres
H, Fuchs E, Körber E and Kolb HJ: Fatty-acid biosynthesis in man, a
pathway of minor importance. Purification, optimal assay
conditions, and organ distribution of fatty-acid synthase. Biol
Chem Hoppe Seyler. 367:905–912. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chen J, Zhuang D, Cai W, Xu L, Li E, Wu Y
and Sugiyama K: Inhibitory effects of four plants flavonoids
extracts on fatty acid synthase. J Environ Sci (China). 21(Suppl
1): S131–S134. 2009. View Article : Google Scholar
|
|
32
|
Liu ZL, Wang G, Peng AF, Luo QF, Zhou Y
and Huang SH: Fatty acid synthase expression in osteosarcoma and
its correlation with pulmonary metastasis. Oncol Lett. 4:878–882.
2012.PubMed/NCBI
|
|
33
|
Menendez JA and Lupu R: Fatty acid
synthase and the lipogenic phenotype in cancer pathogenesis. Nat
Rev Cancer. 7:763–777. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang Y, Zhang XR, Fu J, Tan W and Zhang W:
Prognostic value of expression of FASE, HER-2/neu, bcl-2 and p53 in
stage I non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi.
26:369–372. 2004.In Chinese. PubMed/NCBI
|
|
35
|
Liu ZY, Zhang GL, Wang MM, Xiong YN and
Cui HQ: MicroRNA-663 targets TGFB1 and regulates lung cancer
proliferation. Asian Pac J Cancer Prev. 12:2819–2823.
2011.PubMed/NCBI
|
|
36
|
Ohdaira H, Nakagawa H and Yoshida K:
Profiling of molecular pathways regulated by microRNA 601. Comput
Biol Chem. 33:429–433. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Huang J, Sun C, Wang S, He Q and Li D:
microRNA miR-10b inhibition reduces cell proliferation and promotes
apoptosis in non-small cell lung cancer (NSCLC) cells. Mol Biosyst.
11:2051–2059. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yang YQ, Qi J, Xu JQ and Hao P:
MicroRNA-142-3p, a novel target of tumor suppressor menin, inhibits
osteosarcoma cell proliferation by down-regulation of FASN. Tumour
Biol. 35:10287–10293. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Mao JH, Zhou RP, Peng AF, Liu ZL, Huang
SH, Long XH and Shu Y: microRNA-195 suppresses osteosarcoma cell
invasion and migration in vitro by targeting FASN. Oncol Lett.
4:1125–1129. 2012.PubMed/NCBI
|
|
40
|
Long XH, Mao JH, Peng AF, Zhou Y, Huang SH
and Liu ZL: Tumor suppressive microRNA-424 inhibits osteosarcoma
cell migration and invasion via targeting fatty acid synthase. Exp
Ther Med. 5:1048–1052. 2013.PubMed/NCBI
|
|
41
|
Wu MF, Yang J, Xiang T, Shi YY and Liu LJ:
miR-21 targets Fas ligand-mediated apoptosis in breast cancer cell
line MCF-7. J Huazhong Univ Sci Technolog Med Sci. 34:190–194.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Mo JS, Alam KJ, Kang IH, Park WC, Seo GS,
Choi SC, Kim HS, Moon HB, Yun KJ and Chae SC: MicroRNA 196B
regulates FAS-mediated apoptosis in colorectal cancer cells.
Oncotarget. 6:2843–2855. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wang Z, Liu M, Zhu H, Zhang W, He S, Hu C,
Quan L, Bai J and Xu N: miR-106a is frequently upregulated in
gastric cancer and inhibits the extrinsic apoptotic pathway by
targeting FAS. Mol Carcinog. 52:634–646. 2013. View Article : Google Scholar
|
|
44
|
Li X, Chen YT, Josson S, Mukhopadhyay NK,
Kim J, Freeman MR and Huang WC: MicroRNA-185 and 342 inhibit
tumorigenicity and induce apoptosis through blockade of the SREBP
metabolic pathway in prostate cancer cells. PLoS One. 8:e709872013.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhang H, Feng Z, Huang R, Xia Z, Xiang G
and Zhang J: MicroRNA-449 suppresses proliferation of hepatoma cell
lines through blockade lipid metabolic pathway related to SIRT1.
Int J Oncol. 45:2143–2152. 2014.PubMed/NCBI
|
